Company: BGLC
Filing Date: 2025-04-15
Form Type: 10-K
Source: 0001477932-25-002725
Chunk: 331

Company: BioNexus Gene Lab Corp
Filing Date: 2025-04-15
Form: 10-K
Item: Item 13
Chunk 331
---
verse stock split basis)*.  12  $17,332,315  $17,191,315 Additional paid in capital      (5,011,891)  (5,011,891)Accumulated deficit      (3,442,620)  (1,844,278)Accumulated other comprehensive losses      (555,000)  (677,294)TOTAL STOCKHOLDERS’ EQUITY      8,322,804   9,657,852              TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY     $10,433,848  $11,399,793 

* Issued and outstanding shares of common stock have been adjusted for the periods prior to July 20, 2023, to reflect the 12-for-1 reverse stock split effected on that date on a retroactive basis as described in Note 12.

See accompanying notes to the consolidated financial statements.

 F-5Table of Contents

BIONEXUS GENE LAB CORP.

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME/(LOSS) 

FOR THE YEAR ENDED DECEMBER 31, 2024 AND 2023 

(Currency expressed in United States Dollars (“US$”)) 

(Audited)

     Year ended      December 31,    Note  2024  2023           REVENUE (including $112,556 and $106,919 of revenue from related parties for the year ended December 31, 2024 and 2023 respectively)  9  $9,510,646  $9,770,806              COST OF REVENUE (including $297,736 and $184,433 of cost of revenue from related parties for the years ended December 31, 2024 and 2023, respectively)      (8,221,125)  (8,441,308)             GROSS PROFIT      1,289,521   1,329,498              OTHER INCOME            Dividend income       68,130   61,409 Interest income      147,641   68,675 Fair value gain on investments in equity securities      69,476